Additional file 9: of Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

Additional file 1: of Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer

May Saung (5961734)
Stephen Muth (5961737)
Ding Ding (346784)
Dwayne Thomas (5961740)
Alex Blair (5961743)
Takahiro Tsujikawa (5809061)
Lisa Coussens (714916)
Elizabeth Jaffee (2029204)
Lei Zheng (106363)

November 2018

Figure S1. PD-1 expression on CD4+ and CD8+ T-cells can increase with the addition of αCSF-1R to GVA...

Additional file 5: of PI3KÎą/Î´ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity

Larissa Carnevalli (179142)
Charles Sinclair (6158843)
Molly Taylor (6158846)
Pablo Gutierrez (6158849)
Sophie Langdon (6158852)
Anna Coenen-Stass (1571842)
Lorraine Mooney (372137)
Adina Hughes (6158855)
Laura Jarvis (6158858)
Anna Staniszewska (5892953)
Claire Crafter (1981513)
Ben Sidders (35030)
Elizabeth Hardaker (6158861)
Kevin Hudson (1629772)
Simon Barry (255454)

December 2018

Table S2. List of differentiated expressed genes in control and AZD8835 treated tumors at day 7 and ...

Additional file 1: of Allogenic Vγ9Vδ2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma

Mohammed Alnaggar (6318086)
Yan Xu (14594)
Jingxia Li (69669)
Junyi He (6318092)
Jibing Chen (6318098)
Man Li (81239)
Qingling Wu (2295583)
Li Lin (111038)
Yingqing Liang (6318101)
Xiaohua Wang (255149)
Jiawei Li (559407)
Yi Hu (58993)
Yan Chen (4308)
Kecheng Xu (3373754)
Yangzhe Wu (162008)
Zhinan Yin (342680)

February 2019

Figure S1. Purity of infused allogenic Vγ9Vδ2 T cells of all 8 treatment courses is > 85%. According...

Additional file 8: of Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

Yasuko Tada (5852297)
Yosuke Togashi (550136)
Daisuke Kotani (5852306)
Takeshi Kuwata (282000)
Eichi Sato (5852309)
Akihito Kawazoe (5852312)
Toshihiko Doi (616029)
Hisashi Wada (5852315)
Hiroyoshi Nishikawa (2938410)
Kohei Shitara (5852318)

October 2018

Figure S5. Kinetic changes of IC molecule expression by CD8+ T cells in both PBMCs and TILs. (DOCX 2...

Additional file 7: of Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

Yasuko Tada (5852297)
Yosuke Togashi (550136)
Daisuke Kotani (5852306)
Takeshi Kuwata (282000)
Eichi Sato (5852309)
Akihito Kawazoe (5852312)
Toshihiko Doi (616029)
Hisashi Wada (5852315)
Hiroyoshi Nishikawa (2938410)
Kohei Shitara (5852318)

October 2018

Figure S4. Kinetic changes of CD45RAâFOXP3âCD4+ T cells and eTreg cells in CD3+ T cells. (DOCX 1...

Additional file 10: of Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

Yasuko Tada (5852297)
Yosuke Togashi (550136)
Daisuke Kotani (5852306)
Takeshi Kuwata (282000)
Eichi Sato (5852309)
Akihito Kawazoe (5852312)
Toshihiko Doi (616029)
Hisashi Wada (5852315)
Hiroyoshi Nishikawa (2938410)
Kohei Shitara (5852318)

October 2018

Figure S7. Kinetic changes of IC molecule expression by eTreg cells in both PBMCs and TILs. (DOCX 10...

Additional file 6: of Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

Yasuko Tada (5852297)
Yosuke Togashi (550136)
Daisuke Kotani (5852306)
Takeshi Kuwata (282000)
Eichi Sato (5852309)
Akihito Kawazoe (5852312)
Toshihiko Doi (616029)
Hisashi Wada (5852315)
Hiroyoshi Nishikawa (2938410)
Kohei Shitara (5852318)

October 2018

Figure S3. Kinetic changes of eTreg cells and PD-1 expression by CD8+ T cells according to therapies...

Additional file 11: of Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

Yasuko Tada (5852297)
Yosuke Togashi (550136)
Daisuke Kotani (5852306)
Takeshi Kuwata (282000)
Eichi Sato (5852309)
Akihito Kawazoe (5852312)
Toshihiko Doi (616029)
Hisashi Wada (5852315)
Hiroyoshi Nishikawa (2938410)
Kohei Shitara (5852318)

October 2018

Figure S8. Comparison of IC expression by eTreg cells between pre-and post-treatment in both PBMCs a...

Additional file 12: of Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

Yasuko Tada (5852297)
Yosuke Togashi (550136)
Daisuke Kotani (5852306)
Takeshi Kuwata (282000)
Eichi Sato (5852309)
Akihito Kawazoe (5852312)
Toshihiko Doi (616029)
Hisashi Wada (5852315)
Hiroyoshi Nishikawa (2938410)
Kohei Shitara (5852318)

October 2018

Figure S9. % of eTreg-cell reduction and % of PD-1 reduction on CD8+ T cells and clinical responses....

Additional file 5: of Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

Yasuko Tada (5852297)
Yosuke Togashi (550136)
Daisuke Kotani (5852306)
Takeshi Kuwata (282000)
Eichi Sato (5852309)
Akihito Kawazoe (5852312)
Toshihiko Doi (616029)
Hisashi Wada (5852315)
Hiroyoshi Nishikawa (2938410)
Kohei Shitara (5852318)

October 2018

Figure S2. Difference in patient characteristics according to eTreg-cell frequency in TIL. (DOCX 129...

Additional file 4: of Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

Yasuko Tada (5852297)
Yosuke Togashi (550136)
Daisuke Kotani (5852306)
Takeshi Kuwata (282000)
Eichi Sato (5852309)
Akihito Kawazoe (5852312)
Toshihiko Doi (616029)
Hisashi Wada (5852315)
Hiroyoshi Nishikawa (2938410)
Kohei Shitara (5852318)

October 2018

Figure S1. Genomic features of patients with GC who received RAM-containing therapies. (DOCX 137 kb

Additional file 1: of Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

Yasuko Tada (5852297)
Yosuke Togashi (550136)
Daisuke Kotani (5852306)
Takeshi Kuwata (282000)
Eichi Sato (5852309)
Akihito Kawazoe (5852312)
Toshihiko Doi (616029)
Hisashi Wada (5852315)
Hiroyoshi Nishikawa (2938410)
Kohei Shitara (5852318)

October 2018

Table S1. Gene list of the Oncomineâ˘ Cancer Research Panel (OCP143). (DOCX 18 kb

Additional file 2: of Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer

May Saung (5961734)
Stephen Muth (5961737)
Ding Ding (346784)
Dwayne Thomas (5961740)
Alex Blair (5961743)
Takahiro Tsujikawa (5809061)
Lisa Coussens (714916)
Elizabeth Jaffee (2029204)
Lei Zheng (106363)

November 2018

Figure S2. PD-1 + CD137+ expression increases when αCSF-1R is administered before and after GVAX vac...

Additional file 6: of Insulin-like growth factor receptor signaling in breast tumor epithelium protects cells from endoplasmic reticulum stress and regulates the tumor microenvironment

Alison Obr (5997791)
Sushil Kumar (197871)
Yun-Juan Chang (2661250)
Joseph Bulatowicz (5997794)
Betsy Barnes (5997797)
Raymond Birge (3530714)
Deborah Lazzarino (5997800)
Emily Gallagher (5997803)
Derek LeRoith (135221)
Teresa Wood (5997806)

November 2018

Figure S3. Reduced IGF-1R in primary tumors does not alter the active T cell population. (A, B) Quan...

Additional file 9: of Tumor stem-like cell-derived exosomal RNAs prime neutrophils for facilitating tumorigenesis of colon cancer

Wei-Lun Hwang (2936724)
Hsin-Yi Lan (6266270)
Wei-Chung Cheng (150004)
Shih-Ching Huang (6266273)
Muh-Hwa Yang (206366)

January 2019

Figure S7. Acquisition of an immunosuppressive phenotype in bone marrow-derived neutrophils upon adm...

Additional file 1: of Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer

May Saung (5961734)
Stephen Muth (5961737)
Ding Ding (346784)
Dwayne Thomas (5961740)
Alex Blair (5961743)
Takahiro Tsujikawa (5809061)
Lisa Coussens (714916)
Elizabeth Jaffee (2029204)
Lei Zheng (106363)

November 2018

Figure S1. PD-1 expression on CD4+ and CD8+ T-cells can increase with the addition of αCSF-1R to GVA...

Additional file 5: of PI3KÎą/Î´ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity

Larissa Carnevalli (179142)
Charles Sinclair (6158843)
Molly Taylor (6158846)
Pablo Gutierrez (6158849)
Sophie Langdon (6158852)
Anna Coenen-Stass (1571842)
Lorraine Mooney (372137)
Adina Hughes (6158855)
Laura Jarvis (6158858)
Anna Staniszewska (5892953)
Claire Crafter (1981513)
Ben Sidders (35030)
Elizabeth Hardaker (6158861)
Kevin Hudson (1629772)
Simon Barry (255454)

December 2018

Table S2. List of differentiated expressed genes in control and AZD8835 treated tumors at day 7 and ...

Additional file 1: of Allogenic Vγ9Vδ2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma

Mohammed Alnaggar (6318086)
Yan Xu (14594)
Jingxia Li (69669)
Junyi He (6318092)
Jibing Chen (6318098)
Man Li (81239)
Qingling Wu (2295583)
Li Lin (111038)
Yingqing Liang (6318101)
Xiaohua Wang (255149)
Jiawei Li (559407)
Yi Hu (58993)
Yan Chen (4308)
Kecheng Xu (3373754)
Yangzhe Wu (162008)
Zhinan Yin (342680)

February 2019

Figure S1. Purity of infused allogenic Vγ9Vδ2 T cells of all 8 treatment courses is > 85%. According...

Additional file 8: of Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

Yasuko Tada (5852297)
Yosuke Togashi (550136)
Daisuke Kotani (5852306)
Takeshi Kuwata (282000)
Eichi Sato (5852309)
Akihito Kawazoe (5852312)
Toshihiko Doi (616029)
Hisashi Wada (5852315)
Hiroyoshi Nishikawa (2938410)
Kohei Shitara (5852318)

October 2018

Figure S5. Kinetic changes of IC molecule expression by CD8+ T cells in both PBMCs and TILs. (DOCX 2...

Additional file 7: of Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

Yasuko Tada (5852297)
Yosuke Togashi (550136)
Daisuke Kotani (5852306)
Takeshi Kuwata (282000)
Eichi Sato (5852309)
Akihito Kawazoe (5852312)
Toshihiko Doi (616029)
Hisashi Wada (5852315)
Hiroyoshi Nishikawa (2938410)
Kohei Shitara (5852318)

October 2018

Figure S4. Kinetic changes of CD45RAâFOXP3âCD4+ T cells and eTreg cells in CD3+ T cells. (DOCX 1...

Additional file 10: of Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

Yasuko Tada (5852297)
Yosuke Togashi (550136)
Daisuke Kotani (5852306)
Takeshi Kuwata (282000)
Eichi Sato (5852309)
Akihito Kawazoe (5852312)
Toshihiko Doi (616029)
Hisashi Wada (5852315)
Hiroyoshi Nishikawa (2938410)
Kohei Shitara (5852318)

October 2018

Figure S7. Kinetic changes of IC molecule expression by eTreg cells in both PBMCs and TILs. (DOCX 10...

Additional file 6: of Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

Yasuko Tada (5852297)
Yosuke Togashi (550136)
Daisuke Kotani (5852306)
Takeshi Kuwata (282000)
Eichi Sato (5852309)
Akihito Kawazoe (5852312)
Toshihiko Doi (616029)
Hisashi Wada (5852315)
Hiroyoshi Nishikawa (2938410)
Kohei Shitara (5852318)

October 2018

Figure S3. Kinetic changes of eTreg cells and PD-1 expression by CD8+ T cells according to therapies...

Additional file 11: of Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

Yasuko Tada (5852297)
Yosuke Togashi (550136)
Daisuke Kotani (5852306)
Takeshi Kuwata (282000)
Eichi Sato (5852309)
Akihito Kawazoe (5852312)
Toshihiko Doi (616029)
Hisashi Wada (5852315)
Hiroyoshi Nishikawa (2938410)
Kohei Shitara (5852318)

October 2018

Figure S8. Comparison of IC expression by eTreg cells between pre-and post-treatment in both PBMCs a...

Additional file 12: of Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

Yasuko Tada (5852297)
Yosuke Togashi (550136)
Daisuke Kotani (5852306)
Takeshi Kuwata (282000)
Eichi Sato (5852309)
Akihito Kawazoe (5852312)
Toshihiko Doi (616029)
Hisashi Wada (5852315)
Hiroyoshi Nishikawa (2938410)
Kohei Shitara (5852318)

October 2018

Figure S9. % of eTreg-cell reduction and % of PD-1 reduction on CD8+ T cells and clinical responses....

Additional file 5: of Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

Yasuko Tada (5852297)
Yosuke Togashi (550136)
Daisuke Kotani (5852306)
Takeshi Kuwata (282000)
Eichi Sato (5852309)
Akihito Kawazoe (5852312)
Toshihiko Doi (616029)
Hisashi Wada (5852315)
Hiroyoshi Nishikawa (2938410)
Kohei Shitara (5852318)

October 2018

Figure S2. Difference in patient characteristics according to eTreg-cell frequency in TIL. (DOCX 129...

Additional file 4: of Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

Yasuko Tada (5852297)
Yosuke Togashi (550136)
Daisuke Kotani (5852306)
Takeshi Kuwata (282000)
Eichi Sato (5852309)
Akihito Kawazoe (5852312)
Toshihiko Doi (616029)
Hisashi Wada (5852315)
Hiroyoshi Nishikawa (2938410)
Kohei Shitara (5852318)

October 2018

Figure S1. Genomic features of patients with GC who received RAM-containing therapies. (DOCX 137 kb

Additional file 1: of Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

Yasuko Tada (5852297)
Yosuke Togashi (550136)
Daisuke Kotani (5852306)
Takeshi Kuwata (282000)
Eichi Sato (5852309)
Akihito Kawazoe (5852312)
Toshihiko Doi (616029)
Hisashi Wada (5852315)
Hiroyoshi Nishikawa (2938410)
Kohei Shitara (5852318)

October 2018

Table S1. Gene list of the Oncomineâ˘ Cancer Research Panel (OCP143). (DOCX 18 kb

Additional file 2: of Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer

May Saung (5961734)
Stephen Muth (5961737)
Ding Ding (346784)
Dwayne Thomas (5961740)
Alex Blair (5961743)
Takahiro Tsujikawa (5809061)
Lisa Coussens (714916)
Elizabeth Jaffee (2029204)
Lei Zheng (106363)

November 2018

Figure S2. PD-1 + CD137+ expression increases when αCSF-1R is administered before and after GVAX vac...

Additional file 6: of Insulin-like growth factor receptor signaling in breast tumor epithelium protects cells from endoplasmic reticulum stress and regulates the tumor microenvironment

Alison Obr (5997791)
Sushil Kumar (197871)
Yun-Juan Chang (2661250)
Joseph Bulatowicz (5997794)
Betsy Barnes (5997797)
Raymond Birge (3530714)
Deborah Lazzarino (5997800)
Emily Gallagher (5997803)
Derek LeRoith (135221)
Teresa Wood (5997806)

November 2018

Figure S3. Reduced IGF-1R in primary tumors does not alter the active T cell population. (A, B) Quan...

Additional file 9: of Tumor stem-like cell-derived exosomal RNAs prime neutrophils for facilitating tumorigenesis of colon cancer

Wei-Lun Hwang (2936724)
Hsin-Yi Lan (6266270)
Wei-Chung Cheng (150004)
Shih-Ching Huang (6266273)
Muh-Hwa Yang (206366)

January 2019

Figure S7. Acquisition of an immunosuppressive phenotype in bone marrow-derived neutrophils upon adm...

Additional file 1: of Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer

May Saung (5961734)
Stephen Muth (5961737)
Ding Ding (346784)
Dwayne Thomas (5961740)
Alex Blair (5961743)
Takahiro Tsujikawa (5809061)
Lisa Coussens (714916)
Elizabeth Jaffee (2029204)
Lei Zheng (106363)

November 2018

Figure S1. PD-1 expression on CD4+ and CD8+ T-cells can increase with the addition of αCSF-1R to GVA...

Additional file 5: of PI3KÎą/Î´ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity

Larissa Carnevalli (179142)
Charles Sinclair (6158843)
Molly Taylor (6158846)
Pablo Gutierrez (6158849)
Sophie Langdon (6158852)
Anna Coenen-Stass (1571842)
Lorraine Mooney (372137)
Adina Hughes (6158855)
Laura Jarvis (6158858)
Anna Staniszewska (5892953)
Claire Crafter (1981513)
Ben Sidders (35030)
Elizabeth Hardaker (6158861)
Kevin Hudson (1629772)
Simon Barry (255454)

December 2018

Table S2. List of differentiated expressed genes in control and AZD8835 treated tumors at day 7 and ...

Additional file 1: of Allogenic Vγ9Vδ2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma

Mohammed Alnaggar (6318086)
Yan Xu (14594)
Jingxia Li (69669)
Junyi He (6318092)
Jibing Chen (6318098)
Man Li (81239)
Qingling Wu (2295583)
Li Lin (111038)
Yingqing Liang (6318101)
Xiaohua Wang (255149)
Jiawei Li (559407)
Yi Hu (58993)
Yan Chen (4308)
Kecheng Xu (3373754)
Yangzhe Wu (162008)
Zhinan Yin (342680)

February 2019

Figure S1. Purity of infused allogenic Vγ9Vδ2 T cells of all 8 treatment courses is > 85%. According...

Additional file 9: of Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

Abstract

Extracted data

Additional file 9: of Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

Abstract

Extracted data

Related items

Related items